Cargando…
Discordance between testosterone measurement methods in castrated prostate cancer patients
Failure to suppress testosterone below 0.7 nM in castrated prostate cancer patients is associated with poor clinical outcomes. Testosterone levels in castrated patients are therefore routinely measured. Although mass spectrometry is the gold standard used to measure testosterone, most hospitals use...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376995/ https://www.ncbi.nlm.nih.gov/pubmed/30673630 http://dx.doi.org/10.1530/EC-18-0476 |
_version_ | 1783395678417846272 |
---|---|
author | Rouleau, Mélanie Lemire, Francis Déry, Michel Thériault, Benoît Dubois, Gabriel Fradet, Yves Toren, Paul Guillemette, Chantal Lacombe, Louis Klotz, Laurence Saad, Fred Guérette, Dominique Pouliot, Frédéric |
author_facet | Rouleau, Mélanie Lemire, Francis Déry, Michel Thériault, Benoît Dubois, Gabriel Fradet, Yves Toren, Paul Guillemette, Chantal Lacombe, Louis Klotz, Laurence Saad, Fred Guérette, Dominique Pouliot, Frédéric |
author_sort | Rouleau, Mélanie |
collection | PubMed |
description | Failure to suppress testosterone below 0.7 nM in castrated prostate cancer patients is associated with poor clinical outcomes. Testosterone levels in castrated patients are therefore routinely measured. Although mass spectrometry is the gold standard used to measure testosterone, most hospitals use an immunoassay method. In this study, we sought to evaluate the accuracy of an immunoassay method to measure castrate testosterone levels, with mass spectrometry as the reference standard. We retrospectively evaluated a cohort of 435 serum samples retrieved from castrated prostate cancer patients from April to September 2017. No follow-up of clinical outcomes was performed. Serum testosterone levels were measured in the same sample using liquid chromatography coupled with tandem mass spectrometry and electrochemiluminescent immunoassay methods. The mean testosterone levels were significantly higher with immunoassay than with mass spectrometry (0.672 ± 0.359 vs 0.461 ± 0.541 nM; P < 0.0001). Half of the samples with testosterone ≥0.7 nM assessed by immunoassay were measured <0.7 nM using mass spectrometry. However, we observed that only 2.95% of the samples with testosterone <0.7 nM measured by immunoassay were quantified ≥0.7 nM using mass spectrometry. The percentage of serum samples experiencing testosterone breakthrough at >0.7 nM was significantly higher with immunoassay (22.1%) than with mass spectrometry (13.1%; P < 0.0001). Quantitative measurement of serum testosterone levels >0.7 nM by immunoassay can result in an inaccurately identified castration status. Suboptimal testosterone levels in castrated patients should be confirmed by either mass spectrometry or an immunoassay method validated at low testosterone levels and interpreted with caution before any changes are made to treatment management. |
format | Online Article Text |
id | pubmed-6376995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63769952019-02-20 Discordance between testosterone measurement methods in castrated prostate cancer patients Rouleau, Mélanie Lemire, Francis Déry, Michel Thériault, Benoît Dubois, Gabriel Fradet, Yves Toren, Paul Guillemette, Chantal Lacombe, Louis Klotz, Laurence Saad, Fred Guérette, Dominique Pouliot, Frédéric Endocr Connect Research Failure to suppress testosterone below 0.7 nM in castrated prostate cancer patients is associated with poor clinical outcomes. Testosterone levels in castrated patients are therefore routinely measured. Although mass spectrometry is the gold standard used to measure testosterone, most hospitals use an immunoassay method. In this study, we sought to evaluate the accuracy of an immunoassay method to measure castrate testosterone levels, with mass spectrometry as the reference standard. We retrospectively evaluated a cohort of 435 serum samples retrieved from castrated prostate cancer patients from April to September 2017. No follow-up of clinical outcomes was performed. Serum testosterone levels were measured in the same sample using liquid chromatography coupled with tandem mass spectrometry and electrochemiluminescent immunoassay methods. The mean testosterone levels were significantly higher with immunoassay than with mass spectrometry (0.672 ± 0.359 vs 0.461 ± 0.541 nM; P < 0.0001). Half of the samples with testosterone ≥0.7 nM assessed by immunoassay were measured <0.7 nM using mass spectrometry. However, we observed that only 2.95% of the samples with testosterone <0.7 nM measured by immunoassay were quantified ≥0.7 nM using mass spectrometry. The percentage of serum samples experiencing testosterone breakthrough at >0.7 nM was significantly higher with immunoassay (22.1%) than with mass spectrometry (13.1%; P < 0.0001). Quantitative measurement of serum testosterone levels >0.7 nM by immunoassay can result in an inaccurately identified castration status. Suboptimal testosterone levels in castrated patients should be confirmed by either mass spectrometry or an immunoassay method validated at low testosterone levels and interpreted with caution before any changes are made to treatment management. Bioscientifica Ltd 2019-01-23 /pmc/articles/PMC6376995/ /pubmed/30673630 http://dx.doi.org/10.1530/EC-18-0476 Text en © 2019 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Research Rouleau, Mélanie Lemire, Francis Déry, Michel Thériault, Benoît Dubois, Gabriel Fradet, Yves Toren, Paul Guillemette, Chantal Lacombe, Louis Klotz, Laurence Saad, Fred Guérette, Dominique Pouliot, Frédéric Discordance between testosterone measurement methods in castrated prostate cancer patients |
title | Discordance between testosterone measurement methods in castrated prostate cancer patients |
title_full | Discordance between testosterone measurement methods in castrated prostate cancer patients |
title_fullStr | Discordance between testosterone measurement methods in castrated prostate cancer patients |
title_full_unstemmed | Discordance between testosterone measurement methods in castrated prostate cancer patients |
title_short | Discordance between testosterone measurement methods in castrated prostate cancer patients |
title_sort | discordance between testosterone measurement methods in castrated prostate cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376995/ https://www.ncbi.nlm.nih.gov/pubmed/30673630 http://dx.doi.org/10.1530/EC-18-0476 |
work_keys_str_mv | AT rouleaumelanie discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT lemirefrancis discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT derymichel discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT theriaultbenoit discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT duboisgabriel discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT fradetyves discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT torenpaul discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT guillemettechantal discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT lacombelouis discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT klotzlaurence discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT saadfred discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT guerettedominique discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients AT pouliotfrederic discordancebetweentestosteronemeasurementmethodsincastratedprostatecancerpatients |